secwatch.observer — SEC 8-K summary
======================================

Issuer:     Senti Biosciences, Inc. (SNTI)
CIK:        0001854270
Form:       8-K
Filed at:   2025-03-20T23:59:59+00:00
Accession:  0001854270-25-000038
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Senti Bio reports Q4 net loss $0.6M; two AML patients remain in remission from SENTI-202 trial
--------------------------------------------------------------------------------

- Q4 net loss $0.6M ($0.67/share); full year net loss $52.8M ($12.03/share).
- SENTI-202 Phase 1: 2 of 3 AML patients achieved MRD-negative CR; both still in remission as of March 2025.
- Raised $47.6M gross from PIPE in Dec 2024; net $45.1M extends cash runway into 2026.
- Cash $48.3M at Dec 31, 2024; received additional $1.5M from CIRM grant in Jan 2025.
- Appointed Jay Cross CFO and Faraz Siddiqui SVP Tech Ops in Feb 2025; added two board members.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1854270/000185427025000038/0001854270-25-000038-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1854270/000185427025000038/snti-20250320.htm
  HTML page:      https://secwatch.observer/filing/0001854270-25-000038

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer